Qiagen

Healthy Q2; profitability guidance upgraded

01/08/24 -"Q2 profitability was above the street’s expectations. A decent performance across most of the segments was offset by a weaker showing from Genomics/NGS. While the 2024 sales guidance was impacted by ..."

PDF page sample
Pages
64
Language
English
Published on
01/08/24
Download
You may also be interested by these reports :
27/02/26
bioMerieux’s Q4 sales met expectations, with top-line growth driven by both segments. Management fulfilled its 2025 commitments and provided 2026 ...
25/02/26
Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy ...
25/02/26
Fresenius delivered solid Q4 25 results, supported by broad-based growth across Kabi and Helios. Biopharma remained the key growth engine, supported ...
24/02/26
FMC delivered a strong Q4 profit beat, with record profitability driven by accelerated FME25+ savings and operational discipline. FY 25 results also ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO